Brasofensine

Jump to: navigation, search
Brasofensine
160px
Legal status
Legal status
  • In general: legal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H20Cl2N2O
Molar mass327.248 g/mol
3D model (JSmol)


Brasofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor. It has been researched for the treatment of Parkinson's Disease, depression and treatment of drug dependence. Phase II trials were conducted in 1996 and brasofensine was shown to be well tolerated at a dose of 4mg, but the current progress of this drug is unknown.[1][1]

See also Tesofensine


References

  1. Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002 Feb;36(2):225-30.

Template:Pharmacology-stub


Linked-in.jpg